Abstract
The preclinical and clinical data for the adriamycin analog (AD 32) will be reviewed and compared to adriamycin. Emphasis will be placed on demonstrated biologic differences that may make AD 32 the better compound for clinical use.
Keywords
- High Performance Liquid Chromatography
- Cardiac Toxicity
- Endomyocardial Biopsy
- Aldoketo Reductase
- Preclinical Rationale
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Supported in part by Contract N01-CM-53839 (Division of Cancer Treatment), and Public Health Service Grant CA-19118 from the National Cancer Institute
The authors wish to acknowledge the invaluable assistance of Ms. Carol McCormick tor her data management, and Ms. Martha J. Sack for manuscript preparation
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865–872
Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei III E (to be published) Initial clinical evaluation of N-trifluoracetyladriamycin-14-valerate (AD 32), and adriamycin analog. Cancer Treat Rep 63
Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Duxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 88:168–175
Facchinetti T, Mantovani A, Cantoni L, Cantoni R, Salmona M (1978) Intercalation with DNA is a prerequisite for daunomycin, adriamycin and its congeners in inhibiting DNAase I. Chem Biol Interact 20:97–102
Frei III E, Luce JK, Middleman E (1972) Clinical trials of adriamycin. In: Carter SK, DiMarco A, Ghione M, Krakoff IH, Mathe G (eds) International symposium of adriamycin. Springer, Berlin Heidelberg New York, pp 153–160
Garnick MB, Israel M, Pegg WJ, Blum RH, Smith E, Frei III E (1979) Hepatobiliary pharmacokinetics of AD 32 in man. Proc Am Assoc Cancer Res 20:206
Henderson IC, Billingham M, Israel M, Krishan A, Frei III E (1978) Comparative cardiotoxicity studies with adriamycin (ADR) and AD 32 in rabbits. Proc Am Assoc Cancer Res 19:158
Israel M, Garnick MB, Pegg WJ, Blum RH, Frei III E (1978) Preliminary pharmacology of AD 32 in man. Proc Am Assoc Cancer Res 19:160
Israel M, Modest EJ, Frei III E (1975) N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res 35:1365–1368
Israel M, Pegg WJ, Wilkinson PM, Garnick MB (1979) HPLC applications in the analysis of adriamycin and analogs in biological fluids. In: Hawk GL (ed) Biological-biomedical applications of liquid chromatography. Dekker, New York, pp 413–428
Israel M, Pegg WJ, Wilkinson PM (1978) Urinary anthracycline metabolites from mice treated with adriamycin and N-trifluoroacetyladriamycin-14-valerate. J Pharmacol Exp Ther 204:696–701
Israel M, Wilkinson PM, Osteen RT (1978) Comparative pharmacology of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the monkey. Int Cancer Congr (Abstr) 1:279
Israel M, Wilkinson PM, Pegg WJ, Frei III E (1978) Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat. Cancer Res 38:365–370
Krishan A, Dutt K, Israel M Personal communication
Krishan A, Ganapathi RN, Israel M (1978) Effect of adriamycin and analogs on the nuclear fluorescence of propidium iodide-stained cells. Cancer Res 38:3656–3662
Krishan A, Israel M, Modest EJ, Frei III E (1976) Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyl-adriamycin-14-valerate. Cancer Res 36:2114–2116
Lazarus H, Yuan G, Tan E, Israel M (1978) Comparative inhibitory effects of adriamycin, AD 32, and related compounds on in vitro cell growth and macromolecular synthesis. Proc Am Assoc Cancer Res 19:159
Meriwether WD, Bachur NR (1972) Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L-1210 mouse leukemia. Cancer Res 32:1137–1142
Parker LM, Hirst M, Israel M (1978) N-trifluoroaeetyladriamycin-14-valerate: Additonal mouse antitumor and toxicity studies. Cancer Treat Rep 62:119–127
Sengupta SK, Seshadri R, Modest EJ, Israel M (1976) Comparative DNA-binding studies with adriamycin (ADR), N-trifluoroacetyladriamycin-14-valerate (AD 32) and related compounds. Proc Am Assoc Cancer Res 17:109
Vecchi A, Cairo M, Mantovani A, Sironi M, Spreafico F (1978) Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Treat Rep 62:111–117
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Blum, R.H., Garnick, M.B., Israel, M., Panellos, G.P., Henderson, I.C., Frei, E. (1981). Preclinical Rationale and Phase I Clinical Trial of the Adriamycin Analog, AD 32. In: Carter, S.K., Sakurai, Y., Umezawa, H. (eds) New Drugs in Cancer Chemotherapy. Recent Results in Cancer Research, vol 76. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81565-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-81565-2_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81567-6
Online ISBN: 978-3-642-81565-2
eBook Packages: Springer Book Archive